CLSN Key Statistics, Chart & Performance
The current stock price of CLSN is 1.96 USD. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.
CLSN Latest News, Press Relases and Analysis
CLSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CLSN
Company Profile
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Company Info
CELSION CORP
997 Lenox Dr Ste 100
Lawrence Township NEW JERSEY 08648 US
CEO: Michael H. Tardugno
Employees: 29
Phone: 16098969100.0
CELSION CORP / CLSN FAQ
What does CLSN do?
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
What is the current price of CLSN stock?
The current stock price of CLSN is 1.96 USD.
Does CLSN stock pay dividends?
CLSN does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLSN stock?
CLSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CLSN stock to perform?
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.
Can you provide the sector and industry classification for CELSION CORP?
CELSION CORP (CLSN) operates in the Health Care sector and the Biotechnology industry.
Is CELSION CORP (CLSN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLSN.
CLSN Technical Analysis
CLSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSN. CLSN may be in some trouble as it scores bad on both profitability and health.
CLSN Financial Highlights
Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5229.82% | ||
| ROA | -40.03% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
CLSN Forecast & Estimates
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.